Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.49), $0.10 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist